| Filings | Filing Date | Form Type | Company | Description | AI | Link |
|---|---|---|---|---|---|---|
| Filings | Description | AI | Link | |||
|---|---|---|---|---|---|---|
 HRTXHERON THERAPEUTICS, INC. /DE/ 1.01Material agreement3.03Rights of holders modified7.01Reg FD+1Exhibits:EX-10.1EX-10.2+5 | Nov 9, 20267:40 AM ET | 8-K | HRTX HERON THERAPEUTICS, INC. /DE/ | 1.01Material agreement3.03Rights of holders modified7.01Reg FD+1Exhibits:EX-10.1EX-10.2+5 | ||
 BPOPPOPULAR, INC. 8.01Other events9.01Exhibits | Nov 9, 20267:39 AM ET | 8-K | BPOP POPULAR, INC. | 8.01Other events9.01Exhibits Popular, Inc. filed an 8-K disclosing that a quick service restaurant borrower of Banco Popular de Puerto Rico substantially ceased operations and filed for Chapter 11 bankruptcy a… | ||
 IBRXImmunityBio, Inc. 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:39 AM ET | 8-K | IBRX ImmunityBio, Inc. | 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | ||
 VRDNViridian Therapeutics, Inc.\DE 7.01Reg FD8.01Other events9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:33 AM ET | 8-K | VRDN Viridian Therapeutics, Inc.\DE | 7.01Reg FD8.01Other events9.01ExhibitsExhibits:EX-99.1 Viridian Therapeutics announced positive phase 1 results for VRDN-008, a half-life extended bispecific FcRn inhibitor, showing 74% peak IgG reduction and a 15-18 day half-life in h… | ||
 GTGOODYEAR TIRE & RUBBER CO /OH/ 5.02Officer/director change7.01Reg FD9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:32 AM ET | 8-K | GT GOODYEAR TIRE & RUBBER CO /OH/ | 5.02Officer/director change7.01Reg FD9.01ExhibitsExhibits:EX-99.1 | ||
 ANTXAN2 Therapeutics, Inc. 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:31 AM ET | 8-K | ANTX AN2 Therapeutics, Inc. | 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | ||
 SLNHSoluna Holdings, Inc 7.01Reg FD9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:30 AM ET | 8-K | SLNH Soluna Holdings, Inc | 7.01Reg FD9.01ExhibitsExhibits:EX-99.1 Soluna Holdings announced it will release its third quarter 2026 financial results on Monday, November 16, 2026, followed by a conference call and webcast at 5:00 PM ET. The filing… | ||
 NCPLNetcapital Inc. 3.01Delisting notice9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:30 AM ET | 8-K | NCPL Netcapital Inc. | 3.01Delisting notice9.01ExhibitsExhibits:EX-99.1 | ||
 AZRAzora Therapeutics, Inc. 5.02Officer/director change8.01Other events9.01Exhibits | Nov 9, 20267:30 AM ET | 8-K | AZR Azora Therapeutics, Inc. | 5.02Officer/director change8.01Other events9.01Exhibits | ||
 INOINOVIO PHARMACEUTICALS, INC. 1.01Material agreement7.01Reg FD8.01Other events+1Exhibits:EX-1.1EX-4.1+3 | Nov 9, 20267:30 AM ET | 8-K | INO INOVIO PHARMACEUTICALS, INC. | 1.01Material agreement7.01Reg FD8.01Other events+1Exhibits:EX-1.1EX-4.1+3 | ||
 AVIRAtea Pharmaceuticals, Inc. 1.01Material agreement2.03Direct financial obligation9.01ExhibitsExhibits:EX-10.1 | Nov 9, 20267:30 AM ET | 8-K | AVIR Atea Pharmaceuticals, Inc. | 1.01Material agreement2.03Direct financial obligation9.01ExhibitsExhibits:EX-10.1 | ||
 OCULOCULAR THERAPEUTIX, INC 5.02Officer/director change | Nov 9, 20267:28 AM ET | 8-K | OCUL OCULAR THERAPEUTIX, INC | 5.02Officer/director change | ||
 SLXNSilexion Therapeutics Corp 8.01Other events9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:26 AM ET | 8-K | SLXN Silexion Therapeutics Corp | 8.01Other events9.01ExhibitsExhibits:EX-99.1 Silexion Therapeutics (NASDAQ: SLXN) announced a 1-for-24 reverse share split, effective after market close on November 10, 2026, with split-adjusted trading beginning at market op… | ||
 CDLRCadeler plc | Nov 9, 20267:21 AM ET | 6-K | CDLR Cadeler plc | |||
CDLRCadeler A/S | Nov 9, 20267:21 AM ET | 6-K | CDLR Cadeler A/S | |||
 TNXPTonix Pharmaceuticals Holding Corp. 2.02Results of operations9.01ExhibitsExhibits:EX-99.01 | Nov 9, 20267:20 AM ET | 8-K | TNXP Tonix Pharmaceuticals Holding Corp. | 2.02Results of operations9.01ExhibitsExhibits:EX-99.01 | ||
 CGEMCullinan Therapeutics, Inc. 7.01Reg FD8.01Other events9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:20 AM ET | 8-K | CGEM Cullinan Therapeutics, Inc. | 7.01Reg FD8.01Other events9.01ExhibitsExhibits:EX-99.1 Cullinan Therapeutics announced positive interim clinical data from Genrix Bio's Phase 1b/2a trial of velinotamig (BCMAxCD3 T cell engager) in refractory systemic lupus erythematos… | ||
 FTHFaeth Therapeutics, Inc. 7.01Reg FD9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:19 AM ET | 8-K | FTH Faeth Therapeutics, Inc. | 7.01Reg FD9.01ExhibitsExhibits:EX-99.1 Faeth Therapeutics reported positive preliminary Phase 2 topline results for PIKTOR (serabelisib plus sapanisertib) combined with paclitaxel in advanced endometrioid endometrial ca… | ||
 FACTFACT II Acquisition Corp. 8.01Other events9.01ExhibitsExhibits:EX-10.1 | Nov 9, 20267:17 AM ET | 8-K | FACT FACT II Acquisition Corp. | 8.01Other events9.01ExhibitsExhibits:EX-10.1 FACT II Acquisition Corp. filed an 8-K ahead of its November 17, 2026 extraordinary meeting to approve extending its business combination deadline from November 27, 2026 to Novembe… | ||
 ROIVRoivant Sciences Ltd. 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 | Nov 9, 20267:17 AM ET | 8-K | ROIV Roivant Sciences Ltd. | 2.02Results of operations9.01ExhibitsExhibits:EX-99.1 |
Searching Signal8’s SEC filing archive — filings from Oct 2021 onward.
1-20 of 10,000+ filings